Mette Richner

Mette Richner

Auto-generated profile, based on publicly available information

Mette Richner

DANDRITE, Department of Biomedicine, Aarhus University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
MRMette Richner
Mette Richner
LPLone T. Pallesen
Lone T. Pallesen
MUMaj Ulrichsen
Maj Ulrichsen
EPEbbe T. Poulsen
Ebbe T. Poulsen
THThomas H. Holm
Thomas H. Holm
ANAnders Nykjær
Anders Nykjær
Blocking of sortilin ligand binding prevents neuropathic pain by inhibiting BDNF-induced spinal KCC2 down-regulation.

29 May 2019 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
NGNádia Gonçalves
Nádia Gonçalves
SMSimin Mohseni
Simin Mohseni
Marwa El SouryMarwa El Soury
Marwa El Soury
MUMaj Ulrichsen
Maj Ulrichsen
MRMette Richner
Mette Richner
CVChristian Bjerggaard Vægter
Christian Bjerggaard Vægter
Schwann cell reprogramming and differentiation are crucial prerequisites for neuronal regeneration and re-myelination to occur following injury to peripheral nerves. The neurotrophin receptor p75NTR has been identified as a positive modulator for Schwann cell myelination during development and implicated in promoting nerve regeneration after injury. However, most studies base this conclusion on results obtained from complete p75NTR knockout mouse models and cannot dissect the specific role of p75NTR expressed by Schwann cells. In this present study, a conditional knockout model selectively deleting p75NTR expression in Schwann cells was generated, where p75NTR expression is replaced with that of an mCherry reporter. Silencing of Schwann cell p75NTR expression was confirmed in the sciatic nerve in vivo and in vitro, without altering axonal expression of p75NTR. No difference in sciatic nerve myelination during development or following sciatic nerve crush injury was observed, as determined by quantification of both myelinated and unmyelinated nerve fiber densities, myelinated axonal diameter and myelin thickness. However, the absence of Schwann cell p75NTR reduced motor nerve conduction velocity after crush injury. Our data indicate that the absence of Schwann cell p75NTR expression in vivo is not critical for axonal regrowth or remyelination following sciatic nerve crush injury, but does play a key role in functional recovery. Overall, this represents the first step in redefining the role of p75NTR in the peripheral nervous system, suggesting that the Schwann cell-axon unit functions as a syncytium, with the previous published involvement of p75NTR in remyelination most likely depending on axonal/neuronal p75NTR and/or mutual glial-axonal interactions.

1 August 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
EPEbbe Toftgaard Poulsen
Ebbe Toftgaard Poulsen
NNNadia Sukusu Nielsen
Nadia Sukusu Nielsen
CSCarsten Scavenius
Carsten Scavenius
EMEmilie Hage Mogensen
Emilie Hage Mogensen
MRMichael W. Risør
Michael W. Risør
JEJan J. Enghild
Jan J. Enghild
The serine protease high-temperature requirement protein A1 (HtrA1) is associated with protein-misfolding disorders such as Alzheimer's disease and transforming growth factor β–induced protein (TGFBIp)–linked corneal dystrophy. In this study, using several biochemical and biophysical approaches, including recombinant protein expression, LC-MS/MS and 2DE analyses, and thioflavin T (ThT) fluorescence assays for amyloid fibril detection, and FTIR assays, we investigated the role of HtrA1 both in normal TGFBIp turnover and in corneal amyloid formation. We show that HtrA1 can cleave WT TGFBIp but prefers amyloidogenic variants. Corneal TGFBIp is extensively processed in healthy people, resulting in C-terminal degradation products spanning the FAS1-4 domain of TGFBIp. We show here that HtrA1 cleaves the WT FAS1-4 domain only inefficiently, whereas the amyloidogenic FAS1-4 mutations transform this domain into a considerably better HTRA1 substrate. Moreover, HtrA1 cleavage of the mutant FAS1-4 domains generated peptides capable of forming in vitro amyloid aggregates. Significantly, these peptides have been previously identified in amyloid deposits in vivo, supporting the idea that HtrA1 is a causative agent for TGFBIp-associated amyloidosis in corneal dystrophy. In summary, our results indicate that TGFBIp is an HtrA1 substrate and that some mutations in the gene encoding TGFBIp cause aberrant HtrA1-mediated processing that results in amyloidogenesis in corneal dystrophies.

3 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
GNGith Noes-Holt
Gith Noes-Holt
KJKathrine L. Jensen
Kathrine L. Jensen
MRMette Richner
Mette Richner
RCRaquel Comaposada-Baro
Raquel Comaposada-Baro
LSLine Sivertsen
Line Sivertsen
ASAndreas T. Sørensen
Andreas T. Sørensen
The inadequate state of current pain treatments, the chronic nature of particularly neuropathic pain, and the high impact on quality of life render chronic pain conditions relevant for gene therapy. Here, we describe the development and application of self-assembling dimeric peptide inhibitors of the pain-associated scaffolding protein PICK1 (protein interacting with C-kinase 1) delivered by adeno-associated viral (AAV) vectors. In mice, these peptides prevented mechanical allodynia in inflammatory and neuropathic pain models and reversed neuropathic pain in advanced stages up to one year. Pain relief was obtained by targeting several relays along the somatosensory pain pathways unaccompanied by overt adverse side effects, while selective transduction of peripheral neurons was sufficient for providing full pain relief. We further confirmed PICK1 expression and peptide target engagement in mice and human donor tissue, and we conclude that AAV therapeutics, based on recombinant PICK1 inhibitors, represent a potential clinically meaningful strategy for persistent neuropathic pain conditions. One Sentence Summary Alleviating neuropathic pain by PICK1-directed gene therapy.